• FOXO Technologies posted net revenues of 5.17 million for the three months ended March 31, 2026, up 63.03%, while operating loss narrowed to 276,851.
• Net loss attributable to shareholders widened to 1.45 million, while interest expense climbed to 973,135 on higher borrowings and 0.4 million of default penalties and interest.
• Healthcare segment swung to income of 296,914 on net revenues of 4.8 million, while Life Science Services reported net revenues of 361,250 and segment income of 142,416 following the Vector acquisition.
• Cash fell to 65,896 as of March 31, 2026, while working capital deficit widened to 27.07 million and total debt rose to 8.61 million.
• FOXO entered exchange agreements on May 12, 2026 to swap certain Series A Preferred Stock holdings for senior unsecured non-convertible promissory notes, aiming to address a FINRA denial and resubmit a new reverse stock split notification.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FOXO Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023461), on May 15, 2026, and is solely responsible for the information contained therein.